Novavax, Inc.

NASDAQ:NVAX   3:59:59 PM EDT
42.87
+0.57 (+1.35%)
Products, Regulatory, Earnings Announcements

Novavax Announces Initiation Of Phase 2B/3 Hummingbird Global Clinical Trial For The Novavax COVID-19 Vaccine In Children Aged Six Months Through 11 Years

Published: 08/04/2022 13:23 GMT
Novavax, Inc. (NVAX) - Novavax Announces Initiation of Phase 2b/3 Hummingbird™ Global Clinical Trial for the Novavax Covid-19 Vaccine in Children Aged Six Months Through 11 Years.
Novavax Announces Initiation of Phase 2b/3 Hummingbird™ Global Clinical Trial for Novavax Covid-19 Vaccine in Children Aged Six Months Through 11 Years.
Novavax Inc - Trial Will Seek to Enroll 3,600 Participants in Us, Mexico, Colombia, Argentina, Spain, Uk, South Africa, Philippines, and Brazil.
Novavax Inc - Trial Will Also Have Sentinel Cohorts in Each Age Group and Cohort Progression and Age-de-escalation Will Occur After Safety Review.
Novavax Inc - Initial Results From Phase 2b/3 Hummingbird Global Clinical Trial Are Expected in Q1 2023.
Revenue is expected to be $833.22 Million
Adjusted EPS is expected to be $4.10

Next Quarter Revenue Guidance is expected to be $946.16 Million
Next Quarter EPS Guidance is expected to be $5.86

More details on our Analysts Page.